Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$4.72
-11.1%
$4.36
$1.58
$7.27
$420.75M-0.61.22 million shs1.02 million shs
Innoviva, Inc. stock logo
INVA
Innoviva
$19.15
+0.9%
$18.19
$15.20
$21.28
$1.20B0.35636,735 shs1.04 million shs
MannKind Co. stock logo
MNKD
MannKind
$4.20
+1.9%
$4.70
$4.05
$7.63
$1.25B1.142.37 million shs1.81 million shs
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
$2.05
+11.4%
$1.47
$1.03
$12.02
$222.21M1.021.27 million shs3.76 million shs
(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-11.11%-14.49%-11.94%+47.50%+172.83%
Innoviva, Inc. stock logo
INVA
Innoviva
+0.95%+1.97%+4.99%+6.98%+21.36%
MannKind Co. stock logo
MNKD
MannKind
+1.94%-3.67%-11.39%-23.22%-12.13%
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
+11.41%-0.97%+40.41%-12.02%-70.33%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
3.4547 of 5 stars
3.62.00.00.03.34.21.3
Innoviva, Inc. stock logo
INVA
Innoviva
4.4276 of 5 stars
3.51.00.04.23.52.51.9
MannKind Co. stock logo
MNKD
MannKind
2.7915 of 5 stars
3.61.00.00.02.81.71.9
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
1.6153 of 5 stars
3.50.00.00.02.51.70.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
3.13
Buy$9.83108.33% Upside
Innoviva, Inc. stock logo
INVA
Innoviva
3.00
Buy$55.00187.21% Upside
MannKind Co. stock logo
MNKD
MannKind
3.25
Buy$10.00138.10% Upside
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
3.00
Buy$12.20495.12% Upside

Current Analyst Ratings Breakdown

Latest TNGX, MNKD, AMLX, and INVA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/14/2025
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$7.00 ➝ $8.00
5/9/2025
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$12.00 ➝ $16.00
5/7/2025
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeMarket Perform ➝ Outperform$4.00 ➝ $10.00
5/6/2025
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
4/14/2025
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$13.00 ➝ $13.00
4/10/2025
MannKind Co. stock logo
MNKD
MannKind
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$12.00
4/9/2025
MannKind Co. stock logo
MNKD
MannKind
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeStrong-Buy
4/7/2025
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Outperform$3.00 ➝ $7.00
3/7/2025
Innoviva, Inc. stock logo
INVA
Innoviva
Scotiabank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageSector Outperform$55.00
3/5/2025
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$12.00 ➝ $12.00
(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-$1.27M-330.77$0.86 per share5.51$6.42 per share0.74
Innoviva, Inc. stock logo
INVA
Innoviva
$369.84M3.25$3.70 per share5.17$10.66 per share1.80
MannKind Co. stock logo
MNKD
MannKind
$297.60M4.29N/AN/A($0.91) per share-4.62
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
$40.99M5.42N/AN/A$2.48 per share0.83
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$49.27M-$3.11N/AN/AN/AN/A-36.97%-29.61%8/14/2025 (Estimated)
Innoviva, Inc. stock logo
INVA
Innoviva
$179.72M-$1.0127.7512.35N/A18.31%20.84%11.38%7/29/2025 (Estimated)
MannKind Co. stock logo
MNKD
MannKind
-$11.94M$0.1060.0018.26N/A8.07%-17.74%8.68%8/6/2025 (Estimated)
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
-$101.74M-$1.22N/AN/AN/A-284.42%-49.64%-32.00%8/6/2025 (Estimated)

Latest TNGX, MNKD, AMLX, and INVA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/12/2025Q1 2025
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
-$0.34-$0.36-$0.02-$0.36$6.73 million$5.39 million
5/8/2025Q1 2025
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-$0.45-$0.42+$0.03-$0.42N/AN/A
5/8/2025Q1 2025
MannKind Co. stock logo
MNKD
MannKind
$0.03$0.04+$0.01$0.04$75.86 million$78.35 million
5/7/2025Q1 2025
Innoviva, Inc. stock logo
INVA
Innoviva
N/A$0.25N/A-$0.74N/A$88.63 million
3/4/2025Q4 2024
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
-$0.49-$0.55-$0.06-$0.55N/A($0.67) million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
$1.0221.53%N/AN/A N/A
Innoviva, Inc. stock logo
INVA
Innoviva
N/AN/AN/AN/AN/A
MannKind Co. stock logo
MNKD
MannKind
N/AN/AN/AN/AN/A
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
N/A
4.55
4.55
Innoviva, Inc. stock logo
INVA
Innoviva
0.38
1.79
1.64
MannKind Co. stock logo
MNKD
MannKind
N/A
4.54
4.17
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
N/A
8.00
8.00

Institutional Ownership

CompanyInstitutional Ownership
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
95.84%
Innoviva, Inc. stock logo
INVA
Innoviva
99.12%
MannKind Co. stock logo
MNKD
MannKind
49.55%
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
78.99%

Insider Ownership

CompanyInsider Ownership
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
11.70%
Innoviva, Inc. stock logo
INVA
Innoviva
2.25%
MannKind Co. stock logo
MNKD
MannKind
3.00%
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
6.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
Amylyx Pharmaceuticals, Inc. stock logo
AMLX
Amylyx Pharmaceuticals
20089.14 million60.53 millionOptionable
Innoviva, Inc. stock logo
INVA
Innoviva
10062.78 million61.54 millionOptionable
MannKind Co. stock logo
MNKD
MannKind
400303.93 million267.51 millionOptionable
Tango Therapeutics, Inc. stock logo
TNGX
Tango Therapeutics
90108.39 million100.65 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Amylyx Pharmaceuticals stock logo

Amylyx Pharmaceuticals NASDAQ:AMLX

$4.72 -0.59 (-11.11%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$4.78 +0.07 (+1.38%)
As of 05/27/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Innoviva stock logo

Innoviva NASDAQ:INVA

$19.15 +0.18 (+0.95%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$19.05 -0.10 (-0.50%)
As of 04:47 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

MannKind stock logo

MannKind NASDAQ:MNKD

$4.20 +0.08 (+1.94%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$4.23 +0.03 (+0.71%)
As of 04:58 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults. The company's product pipeline also includes Tyvaso DPI (Treprostinil), an inhalation powder for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; MNKD-101, a nebulized formulation of clofazimine, for the treatment of severe chronic and recurrent pulmonary infections, including nontuberculous mycobacterial lung disease; MNKD-201, a dry-powder formulation of nintedanib, for the treatment of idiopathic pulmonary fibrosis (IPF). In addition, it has collaboration and license agreement with United Therapeutics Corporation for development, regulatory, and commercial activities of Tyvaso DPI; co-promotion agreement with Vertice Pharma to promote Thyquidity; and collaboration agreement with Thirona to evaluate the therapeutic for the treatment of pulmonary fibrosis. Further, the company has supply and distribution agreement with Biomm S.A. for the commercialization of Afrezza in Brazil; and license and distribution agreement with Cipla Ltd. for the marketing and distribution of Afrezza in India. MannKind Corporation was incorporated in 1991 and is headquartered in Danbury, Connecticut.

Tango Therapeutics stock logo

Tango Therapeutics NASDAQ:TNGX

$2.05 +0.21 (+11.41%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$2.05 0.00 (0.00%)
As of 06:00 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.